Precision Medicine in Oncology: Ep.10. Biomarkers in Gastrointestinal Malignancies

IMPACT Medicom

English - February 07, 2022 15:00 - 25 minutes - 17.8 MB
Science impact medicom medical communications medical writing agency Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Precision Medicine in Oncology: Ep.9 DEBATE - Is PARP inhibitor maintenance therapy in first-line BRCA mutated ovarian cancer a curative-intent strategy?

Next Episode: Pre- and Post- COVID-19 Exposure Prophylaxis: Ep1 - Introduction

In this episode of IMPACT Medicom’s Precision Medicine in Oncology podcast series, we discuss the evolving biomarker landscape in gastrointestinal malignancies and some of the advantages and challenges of implementing and accessing biomarker testing.

Our guest:

Dr. Rosalyn Juergens is a medical oncologist with clinical expertise in lung and esophageal cancer. She was on the faculty at The Johns Hopkins Medical Institute from 2007-2010 until she joined the faculty at McMaster University in 2011. Dr. Juergens’ leadership roles include serving as chair of the Lung Disease Site Team and Head of the Department of Clinical Trials at the Juravinski Cancer Centre in Hamilton, Ontario. She is also the chair of the Executive Committee of the Canadian Cancer Trials Group Investigational New Drug Committee and Medical Advisory Committee Chair for Lung Cancer Canada. Dr. Juergens’ research interests involve improving therapeutics and diagnostics in cancer, with a focus on developmental therapeutics and Phase I and II clinical trials.

This podcast episode was sponsored by Merck Canada.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com